12/19
08:05 pm
srpt
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
Low
Report
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory [Yahoo! Finance]
12/14
07:56 pm
srpt
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]
Low
Report
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. [CBS News]
12/14
07:56 pm
srpt
Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]
Low
Report
Breakthrough genetic therapies can save lives, but many cost millions for single dose [CBS News]
12/11
07:00 am
srpt
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Low
Report
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
12/10
12:42 am
srpt
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]
Low
Report
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound [Yahoo! Finance]
12/9
08:19 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) is now covered by analysts at Wedbush. They set an "outperform" rating and a $32.00 price target on the stock.
11/25
08:57 am
srpt
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Low
Report
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
11/24
07:30 am
srpt
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Medium
Report
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
11/20
10:00 am
srpt
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
11/15
11:39 am
srpt
Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]
Medium
Report
Is Sarepta Therapeutics a Bargain After Its 82% Drop Over the Last Year? [Yahoo! Finance]
11/14
03:22 pm
srpt
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]
Low
Report
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance Canada]
11/14
03:20 pm
srpt
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance]
Low
Report
FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths [Yahoo! Finance]
11/14
02:54 pm
srpt
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Medium
Report
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
11/8
01:17 pm
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at
Wall St
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at
Wall St
11/7
01:15 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:00 am
srpt
Sarepta (SRPT) Soars 15% on Bullish Rating [Yahoo! Finance]
Low
Report
Sarepta (SRPT) Soars 15% on Bullish Rating [Yahoo! Finance]
11/5
12:55 pm
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Barclays PLC from $22.00 to $20.00. They now have an "equal weight" rating on the stock.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Barclays PLC from $22.00 to $20.00. They now have an "equal weight" rating on the stock.
11/5
10:49 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Guggenheim from $22.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Guggenheim from $22.00 to $19.00. They now have a "buy" rating on the stock.
11/5
10:49 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Wells Fargo & Company from $50.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by analysts at Wells Fargo & Company from $50.00 to $45.00. They now have an "overweight" rating on the stock.
11/5
08:04 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
High
Report
Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $26.00 price target on the stock.
11/4
05:38 pm
srpt
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following ESSENCE Trial Miss and FDA Discussions [Yahoo! Finance]
High
Report
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following ESSENCE Trial Miss and FDA Discussions [Yahoo! Finance]
11/4
01:43 pm
srpt
Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 [Seeking Alpha]
Low
Report
Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026 [Seeking Alpha]
11/4
08:44 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) was given a new $15.00 price target on by analysts at Robert W. Baird.
Medium
Report
Sarepta Therapeutics (NASDAQ:SRPT) was given a new $15.00 price target on by analysts at Robert W. Baird.
11/3
04:05 pm
srpt
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
High
Report
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
10/30
09:46 am
srpt
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Piper Sandler from $15.00 to $16.00. They now have a "neutral" rating on the stock.
Low
Report
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Piper Sandler from $15.00 to $16.00. They now have a "neutral" rating on the stock.